On 19 November, the Servier group won the M&A DEAL OF THE YEAR award, during the European Lifestars Awards ceremony in London, for last year’s acquisition of Shire’s Oncology branch.
This prestigious award recognizes the teams and organizations who have executed a truly transformational and high-value M&A deal for both the company and the wider pharmaceutical industry.
@lifestarsawards M&A of the Year WINNER! @Servier & @shireplc. Congratulations to you both! Plus, many thanks to our Category sponsor @Mintz_Law #lifestarsawards #biotech #medtech pic.twitter.com/gpnPOOTNFb
— LSX Leaders (@LSXLeaders) November 19, 2019
The annual European Lifestars Awards bring together hundreds of European life science leaders, investors, partners and deal makers.
“It is an honour to receive this distinction from leading investors and pharma key stakeholders. It makes the Servier teams very proud”, says Olivier Laureau, President of Servier. “The acquisition of Shire’s Oncology branch was a major step in achieving the Servier group’s ambition. It marked the launch of Servier’s commercial activities in the world’s largest pharmaceutical market – the United States – and significantly strengthened our portfolio of oncology drugs. It was part of Servier’s twofold strategy: to continue to treat an increasing number of patients with innovative medications across the world and become a world reference in oncology.”
Servier was also finalist in two other categories: Deal of the Year (<500M£) and Pharma BD team of the Year.
More information about Lifestars Awards